Www.postersession.com Noncirrhotic portal hypertension (NCPH) comprises diseases of the liver manifesting with portal hypertension due to intrahepatic.

Slides:



Advertisements
Similar presentations
Non Cirrhotic Portal Hypertension: A Serious Hepatic Complication in HIV and the Use of Transient Elastography for Diagnosis Dronamraju D,Vachon ML, and.
Advertisements

Hepatocirrhosis Liver cirrhosis.
Clinical Course of Untreated BA Phoebe part. Clinical Course of Untreated BA Most present within four to six weeks of conjugated jaundice and acholic.
Bruix J, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 24, 2009, Copenhagen, Denmark.04/28/09.
Dr. David Pearson Gastroenterology, Victoria.  None relevant to this presentation.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington.
Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine.
1M.A.Kubtan. 2 What is TORSO : The body excluding the head and neck and limbs M.A.Kubtan3.
V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.
OSLER RENDU WEBER SYNDROME. AIM To diagnose a rare case of OSLER RENDU WEBER SYNDROME Screening methods for first degree relatives of patients for early.
CREATININE AND CYSTATIN-C BASED GFRs VS 51 Cr-EDTA GFR IN PATIENTS WITH DECOMPENSATED CIRRHOSIS 1 4th Department of Internal Medicine, Hippokration General.
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD Featured Article: Jessica Bazick,
Chronic hepatitis in childhood Modes of presentation Acute onset jaundice and persisting Gradual development of signs of liver disease Asymptomatic finding.
Liver Cirrhosis S. Diana Garcia
Deranged LFTs Pathways A H Mohsen Dr A H Mohsen MD (KCL), MRCP, DTM&H Consultant Gastroenterologist.
Effect of Hepatic Impairment on Sorafenib Pharmacokinetics: Results of a Multicenter, Open-Label, Single-Dose, Phase I Trial J Lettieri, A Mazzu,
CIRRHOSIS OF LIVER PORTAL HYPERTENSION HEPATIC ENCHEPALOPATHY
CASE 4 67 yo man HIV Hypertensive CD4 on diagnosis 110/7% AZT initiated soon after diagnosis.
Severity Index for patients with Liver Cirrhosis disease Health Decision Analysis Yokabid Worku
International Congress Highlights 2004 Clinical Update in GI disease Portal Hypertension P. Michielsen University of Antwerp
SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.
Multiplex Genetic Test in Liver Detoxification Function for Predicting Liver Disease Progression Ran Oren, Hava Peretz, Sigal Fishman, Guy Rosner, Zamir.
Primary Sclerosing Cholangitis
FT in diagnostic of HCV FibroTest in the diagnosis of HCV Publications on diagnostic performance.
Non-invasive methods to assess hepatic fibrosis MIRELLA FRAQUELLI MD PhD - DARIO CONTE MD Gastroenterology and Endoscopy Unit Fondazione IRCCS “Cà Granda”
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
FT in prognostic of HBV FibroTest: predictive value in HBV.
Portal hypertension (PH) is a frequent complication of cirrhosis, contributing to the development of ascites, esophageal varices (EV), and hepatic encephalopathy.
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
Approach to a child with hepatomegaly Dr. Shreedhar Paudel May, 2009.
Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.
Evaluation of risk for esophageal varices by transient elastometry in patients with HIV and HCV infection and liver cirrhosis M.K. Mausolf 1, M. Berger.
Clinical History Patient presents with a palpable upper abdominal mass Patient states possible clinical history of abdominal hernia.
Non-Invasive Liver Testing
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation Ki Tae Yoon, Sun Min Lim,Jun Yong.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Golgi Protein-73 Shows Promise as a Sensitive Serum Marker for HCC Slideset on: Marrero J, Romano P, Nikolaeva O, et al. GP73, a resident golgi glycoprotein,
Alcoholic Liver Disease Prof.Dr. Khalid A. Al-Khazraji MBCHB, CABM, FRCP, FACP Baghdad medical college
HEPATOLOGY, Vol. 61, No. 6, Introduction At least 1 / 3 of liver cirrhosis (LC) Chronic hepatitis B (CHB) Significant proportion of CHB progress.
Approach to Ascites Updated by Daniel Kim, 06/2017.
Interpreting Your Test Results
Dr. Mohammed Omar Khalifa
Diagnostic accuracy and statistical significance
Portal Hypertension.
Figure 1 Proposed risk stratification for patients with NAFLD
NESIR case presentation
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Predictive value of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and mean platelet volume for pelvic inflammatory disease Meryem Hocaoğlu.
Portal Hypertension Dr. HAMID HINDI.
Bariatric Surgery in Cirrhotic Patients. Analysis of 12 cases.
University of Medicine and Pharmacy “Carol Davila”, Bucharest
Longitudinal Transient Elastography measurements (Fibroscan) used in follow-up for patients with Cystic Fibrosis. Stephanie Van Biervliet, Hugo Verdievel,
Samantha King, Jill Jones MD, Russ Waitman PhD
Presented By: Sally Saad Mandour Esawy
Basic laboratory testing
Carcinoma of the Liver By: Renee Alta.
Basic laboratory testing
Successful TACE for HCC
Managing Complications of Cirrhosis
Update on ultrasound imaging of liver fibrosis
Figure 1 Proposed algorithm for the management
Nottingham Digestive Diseases Biomedical Research Unit
Volume 141, Issue 4, Pages e3 (October 2011)
Non-invasive evaluation of liver fibrosis using transient elastography
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba  Gastroenterology 
Primary Sclerosing Cholangitis Interpreting your tests
Presentation transcript:

Noncirrhotic portal hypertension (NCPH) comprises diseases of the liver manifesting with portal hypertension due to intrahepatic or prehepatic lesions in the absence of cirrhosis. Patients with NCPH can mimic cirrhosis on routine imaging like ultrasonography and CT scan. Knowledge of radiologic mimics of cirrhosis is increasingly important because an erroneous diagnosis of cirrhosis in some settings could adversely impact contemporary treatment options. Liver and spleen stiffness (LS and SS) measured by ARFI has similar predictive value to tissue elastography (TE) for detecting significant fibrosis and cirrhosis. The limitations of TE, such as narrow intercostal spaces, ascites and obesity, do not appear to apply to the use of ARFI elastography. There is scarity of data on LS and SS measurements by ARFI in patients with NCPH and its value in predicting presence or absence of esophageal varices as well as bleeding from varices. So, the aim of our study was to measure LS and SS by ARFI elastography in NCPH and whether it helps to correct the erroneous diagnosis of cirrhosis in patients with NCPH. Methods Conclusions Evaluation of liver and spleen stiffness by acoustic radiation force impulse (ARFI) in non cirrhotic portal hypertension (NCPH) Apurva Shah 1, Deepak Amarapurkar1 1. Bombay Hospital and Medical Research center, Mumbai,India Bibliography A prospective study conducted at single tertiary hospital in department of Gastroenterology and Radiology. 171 patients undergoing liver biopsy for evaluation of liver disease with or without portal hypertension (cirrhosis and NCPH) were subjected to LS and SS measurement by ARFI prior to biopsy. History, physical examination, relevant blood investigations, esophagogastroduodenoscopy and imaging (ultrasonography and Doppler (whenever indicated)) were done in all patients. Sixty one age matched patients who had undergone ultrasonography as a part of routine health check-up and had normal liver function test, hepatitis B & C serology negative, no history of alcohol consumption and BMI within a normal range and normal findings on ultrasonography served as control. LS and SS measurement by ARFI: After six hours of fasting, patients underwent complete upper abdominal US. Immediately after US, ARFI elastography was performed with Acuson S2000 high- density ultrasound system. For evaluation of LS, ARFI scanning was done in the intercostal space in the right lobe of liver with minimal scanning pressure applied by the operator, patient lying in the dorsal decubitus position, right arm maximally abducted and the patient was asked to hold breath for a moment. A measurement depth of 2-3 cm below the liver capsule was chosen to standardize the examination. Similarly, SS was taken in intercostal spaces, 1 cm below splenic capsule, with patient lying in right decubitus and arm maximally abducted. The Acuson S2000 has a memory capability and more than five successful, usually ten acquisitions, was performed for each patients and the mean value of LS and SS was calculated in m/sec. P value of less than.05 was considered to indicate a significant difference. 1.Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al. Members of the APASL working party on portal hypertension. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006; 26: Jha P, Poder L, Wang ZJ, Westphalen AC, Yeh BM, Coakley FV. Radiologic mimics of cirrhosis. AJR Am J Roentgenol ; 194(4): Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, et al. Meta- analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33(8): Bodh, V. and Chawla, Y. Noncirrhotic intrahepatic portal hypertension.Clinical Liver Disease.2014; 3: 129– Khanna R, Sarin SK. Non-cirrhotic portal hypertension—diagnosis and management. J Hepatol 2014;60: Patients with NCPH had higher LS and SS values compared to that of the healthy subjects and lower LS as compared to cirrhotics. Patients with variceal bleed in NCPH had higher SS values than did those without bleed. So, SS could be more reliable indicator in presinusoidal disease and SS can be used to discriminate patients with a bleed from those without a bleed with high sensitivity and specificity in NCPH patients. LS and SS values does not differentiate small and large esophageal varices in NCPH. Most patients of NCPH who had undergone liver biopsy had no fibrosis. LS and SS were not significantly different in different stages of fibrosis in NCPH patients. Mean LS in NCPH group who had fibrosis stage 0 was lower than that of cirrhotic patients but the difference was not significant. In conclusion, LS and SS measurement by ARFI helps to correct erroneous diagnosis of cirrhosis in NCPH when used in context of clinical examination, liver function test and colour Doppler ultrasonography and also helps to predict patients with variceal bleed. Introduction Results Table 1: Demographic and biochemical profile Table 2: Size of esophageal varices, ARFI and APRI in NCPH Order online at Parameters NCPH subjects (n= 40) Control subjects (n = 61) P value Mean age (y)39.7 ± 14.4 (14-77)41.6 ± 17.9 (18-81).641 Male-to-female ratio20: 2042:19 BMI ( kg/ m 2 )22.1 ± ± Median hemoglobin (g/dL) 10.9 (6-16)13 (8-16).004 Median total leukocyte count (mm 3 /dL) 6035( )8200 ( ).064 Median platelet count (thousands/mL) Mean total bilirubin (mg/dL) 1 ± ± Median aspartate aminotransferase (IU/l) 30(15-84)24(14-90).143 Median alanine aminotransferase (IU/l) 38 (15-97)30 (15-291).189 Mean serum albumin (g/dL) 3.8 ± ± Mean LS (m/s)1.7± ± Mean SS (m/s)3.4 ± ± APRI0.7 ± ± VaricesLS (m/s), n = 21SS (m/s), n = 21APRI (n = 21) small1.67 ± ± ± large1.85 ± ± ± P value (SS was available for 21 patients as 16 patients had undergone splenectomy and 3 subjects had no varices) Table 3: Variceal bleed and ARFI in NCPH Variceal bleedLS (m/s), n = 21SS (m/s), n = 21APRI (n = 21) Yes (n = 6)1.54 ± ± ± No (n = 15)1.87 ± ± ± P value Table 4: Association between ARFI values with fibrosis and diagnosis Fibrosis stage Mean ARFI values – LS (m/s) ( mean  SD) NNCPF,EHPOVN Others (Cirrhosis)           0.60 By Student t test P = 0.126, Not Significant